SCHEMBL5335652

SCHEMBL5335652

CC(C)(C)[SiH2]OC(C)(C)c1cc(-c2c(Cl)cccc2Cl)no1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.40
MAPT P10636 6/20 0.40
MEN1 O00255 5/20 0.40
POLB P06746 4/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
MAPK14 Q16539 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
HTT P42858 3/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
BRD4 O60885 1/20 0.31
LMNA P02545 1/20 0.31
RECQL P46063 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TSHR P16473 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5334515 0.91 CHRNB2 (0.38) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL5327891 0.79 MAPT (0.43) KMT2AMAPTMEN1POLBALDH1A1
SCHEMBL5331361 0.77 CNR2 (0.38) KMT2AMAPTMEN1ALDH1A1CHRNB2
SCHEMBL5332143 0.69 GALR3 (0.34) KMT2AMAPTMEN1LMNASMN1; SMN2
SCHEMBL23302623 0.68 SMN1; SMN2 (0.47) KMT2AMAPTMEN1POLBALDH1A1
SCHEMBL10163467 0.68 RAB9A (0.49) KMT2AMAPTMEN1POLBALDH1A1
SCHEMBL2324549 0.67 ALDH1A1 (0.33) ALDH1A1MAPK1SMN1; SMN2
SCHEMBL2332738 0.67 NOTUM (0.35)
SCHEMBL2326700 0.67
SCHEMBL5465268 0.66 ALDH1A1 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007034445-A2 NOVEL PIPERAZINE DERIVATIVES AS RENIN INHIBITORS FOR CARDIOVASCULAR EVENTS AND RENAL INSUFFICIENCY ACTELION PHARMACEUTICALS LTD (CH) 2007-03-29 WO disclosed